CANNABIS
Cannabis medicinal extract effective in improving some neurogenic symptoms - a pilot study
Clin Rehabil. 2003 Feb;17(1):21-9.24 patients diagnosed with neurological diagnosis and unresponsive to standard treatments were recruited and received four 2-week treatments. Patients were randomly assigned to receive sublingual sprays of either delta-9-tetrahydrocannabinol (THC) only, cannabidiol (CBD) only, 1:1 THC and CBD preparation, or placebo during each 2-week treatment session. Results demonstrated that compared to placebo, there was a significantly greater improvement of pain in the CBD group and the THC group, spasm in the THC group and the THC:CBD group, and spasticity in the THC group. There was no significant difference in improving bladder control and coordination between any of the 3 treatment groups compared to placebo.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
